Clinical OMICS

MAY-JUN 2019

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1117801

Contents of this Issue

Navigation

Page 8 of 50

www.clinicalomics.com May/June 2019 Clinical OMICs 7 PathAI's Series B to Fund AI Platform for Pathology AI-based platform for pathology develop- er PathAI has raised $60 million in Series B financing it says will help fuel continu- ing expansion efforts to help pathologists diagnose and sub-type cancer and other diseases quickly and accurately. PathAI said proceeds from the financing will en- able it to enhance its offerings to existing partners—which include pharma giants Bristol-Myers Squibb and Novartis—and improve its flagship research platform, and support R&D into new tools and med- ical devices. PathAI also partners with Philips on deep learning applications in computa- tional pathology designed to improve the precision and accuracy of routine diagno- sis of cancer and other disease and with the Bill and Melinda Gates Foundation on enhancing access to advanced diagnostic services at a sustainable cost for people in developing countries. n Dozens of Genetic Links to Sleep Patterns Found An international team of investigators led by scientists at the University of Exeter in the U.K. found 47 links between our genetic code and the quality, quantity, and timing of how we sleep. These include ten new genetic links with sleep duration and 26 with sleep quality. "We know that getting enough sleep improves our health and wellbeing, yet we still know relatively little about the mechanisms in our bodies that influence how we sleep," explained lead study investigator Andrew Wood, Ph.D., a lecturer at the University of Ex- eter. "Changes in sleep quality, quantity, and timing are strongly associated with several human diseases such as diabetes and obesity, as well as psychiatric disorders." The genome-wide association study (GWAS) reviewed data from 85,670 participants of UK Biobank and 5,819 individuals from three other studies, who wore accelerome- ters—wrist-worn devices similar to a Fitbit which record activity levels continuously for seven days. n Sherlock Biosciences Raises $31M for CRISPR Dx Development Sherlock Biosciences (see also p. 47 "10 to Watch"), the CRISPR-based diagnostics developer whose co-founders include a pioneer of the gene editing technology, Feng Zhang, Ph.D., said it has completed a $31 million Series A financing, bringing to $49 million its total capital committed by investors. Sherlock said the capital will be used to advance development programs for the company's core platform technolo- gies. These include SHERLOCK (Specific High-sensitivity Enzymatic Reporter un- LOCKing), a method for identifying specif- ic sequences of genetic material in a sam- ple using CRISPR; and INSPECTR (INternal Splint-Pairing Expression Cassette Transla- tion Reaction), which can be programmed to distinguish targets based on a single nucleotide at room temperature, without laboratory equipment. Sherlock will leverage synthetic biol- ogy and intellectual property related to CRISPR patents held by the Broad Insti- tute of MIT and Harvard, where Zhang is based, and Harvard University's Wyss Institute for Biologically Inspired Engi- neering. The company aims to create a new generation of molecular diagnostics that can rapidly deliver accurate and inexpen- sive results for a vast range of needs in virtually any setting. Potential applica- tions identified by Sherlock include on- cology, infectious disease, low-resource settings, and at-home testing. n drogatnev / iStock / Getty Images Noppon Kobpimai / EyeEm / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAY-JUN 2019